The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy

Frontiers in Immunology

Volumn 9, Issue JAN, 2018, Pages

  Hornyák, Lilla ^a   Dobos, Nikoletta ^b   Koncz, Gábor ^a   Karányi, Zsolt ^a   Páll, Dénes ^a   Szabó, Zoltán ^a   Halmos, Gábor ^b   Székvölgyi, Lóránt ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Cancer diagnostics; Clinical trial; Gene expression; Immune surveillance; Immunotherapy; Indoleamine 2,3 dioxygenase; Metabolism

Indexed keywords

CD40 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; TRANSCRIPTION FACTOR FKHRL1;

BIOCHEMISTRY; CANCER IMMUNOTHERAPY; CELL MATURATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; ENZYME ACTIVITY; ENZYME REGULATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; MALIGNANT NEOPLASM; PROTEIN EXPRESSION; SHORT SURVEY;

EID: 85041621018     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.00151     Document Type: Short Survey

References (67)

1. Zhai L, Spranger S, Binder DC, Gritsina G, Lauing KL, Giles FJ, et al. Molecular pathways: targeting IDO1 and Other tryptophan dioxygenases for cancer immunotherapy. Clin Cancer Res (2015) 21:5427-33. doi:10.1158/1078-0432.CCR-15-0420
2. Bilir C, Sarisozen C. Indoleamine 2,3-dioxygenase (IDO): only an enzyme or a checkpoint controller?. J Oncol Sci (2017) 3:52-6. doi:10.1016/j.jons.2017.04.001
3. Yevshin I, Sharipov R, Valeev T, Kel A, Kolpakov FGTRD. A database of transcription factor binding sites identified by ChIP-seq experiments. Nucleic Acids Res (2017) 45:D61-7. doi:10.1093/nar/gkw951
4. van Baren N, Van den Eynde BJ. Tryptophan-degrading enzymes in tumoral immune resistance. Front Immunol (2015) 6:34. doi:10.3389/fimmu.2015.00034
5. Thul PJ, Akesson L, Wiking M, Mahdessian D, Geladaki A, Ait Blal H, et al. A subcellular map of the human proteome. Science (2017) 356:eaal3321. doi:10.1126/science.aal3321
6. Zulfiqar B, Mahroo A, Nasir K, Farooq RK, Jalal N, Rashid MU, et al. Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors. Onco Targets Ther (2017) 10:463-76. doi:10.2147/OTT.S119362
7. Vogel CFA, Wu D, Goth SR, Baek J, Lollies A, Domhardt R, et al. Aryl hydrocarbon receptor signaling regulates NF-κB RelB activation during dendritic-cell differentiation. Immunol Cell Biol (2013) 91:568-75. doi:10.1038/icb.2013.43
8. Pallotta MT, Fallarino F, Matino D, Macchiarulo A, Orabona C. AhR-mediated, non-genomic modulation of IDO1 function. Front Immunol (2014) 5:497. doi:10.3389/fimmu.2014.00497
9. Dixon JR, Jung I, Selvaraj S, Shen Y, Antosiewicz-Bourget JE, Lee AY, et al. Chromatin architecture reorganization during stem cell differentiation. Nature (2015) 518:331-6. doi:10.1038/nature14222
10. Thomas SR, Mohr D, Stocker R. Nitric oxide inhibits indoleamine 2, 3-dioxygenase activity in interferon-gamma primed mononuclear phagocytes. J Biol Chem (1994) 269:14457-64.
11. Thomas SR, Terentis AC, Cai H, Takikawa O, Levina A, Lay PA, et al. Post-translational regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide. J Biol Chem (2007) 282:23778-87. doi:10.1074/jbc. M700669200
12. Hucke C, MacKenzie CR, Adjogble KDZ, Takikawa O, Däubener W. Nitric oxide-mediated regulation of gamma interferon-induced bacteriostasis: inhibition and degradation of human indoleamine 2,3-dioxygenase. Infect Immun (2004) 72:2723-30. doi:10.1128/IAI.72.5.2723-2730.2004
13. Genes P, Liu SF, Ye X, Malik AB. Inhibition of NF-kB activation by pyrrolidine dithiocarbamate prevents in vivo expression of. Circulation (1999) 100:1330-7. doi:10.1161/01.CIR.100.12.1330
14. Thomas SR, Salahifar H, Mashima R, Hunt NH, Richardson DR, Stocker R. Antioxidants inhibit indoleamine 2,3-dioxygenase in IFN-gamma-activated human macrophages: posttranslational regulation by pyrrolidine dithiocarbamate. J Immunol (2001) 166:6332-40. doi:10.4049/jimmunol.166.10.6332
15. Fujigaki H, Saito K, Lin F, Fujigaki S, Takahashi K, Martin BM, et al. Nitration and inactivation of IDO by peroxynitrite. J Immunol (2006) 176:372-9. doi:10.4049/jimmunol.176.1.372
16. Grohmann U, Fallarino F, Bianchi R, Orabona C, Vacca C, Fioretti MC, et al. A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J Exp Med (2003) 198:153-60. doi:10.1084/jem.20030633
17. Schmidt SK, Ebel S, Keil E, Woite C, Ernst JF, Benzin AE, et al. Regulation of IDO activity by oxygen supply: inhibitory effects on antimicrobial and immunoregulatory functions. PLoS One (2013) 8:e63301. doi:10.1371/journal.pone.0063301
18. Herbert A, Ng H, Jessup W, Kockx M, Cartland S, Thomas SR, et al. Hypoxia regulates the production and activity of glucose transporter-1 and indoleamine 2,3-dioxygenase in monocyte-derived endothelial-like cells: possible relevance to infantile haemangioma pathogenesis. Br J Dermatol (2011) 164:308-15. doi:10.1111/j.1365-2133.2010.10086.x
19. Roman J, Rangasamy T, Guo J, Sugunan S, Meednu N, Packirisamy G, et al. T-cell activation under hypoxic conditions enhances IFN-γ secretion. Am J Respir Cell Mol Biol (2010) 42:123-8. doi:10.1165/rcmb.2008-0139OC
20. Orabona C, Pallotta MT, Volpi C, Fallarino F, Vacca C, Bianchi R, et al. SOCS3 drives proteasomal degradation of indoleamine 2, 3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci U S A (2008) 105:20828-33. doi:10.1073/pnas.0810278105
21. Maria P, CIriana O, Claudia V, Ursula G, Paolo P, Francesca F. Proteasomal degradation of indoleamine 2,3-dioxygenase in CD8+ dendritic cells is mediated by suppressor of cytokine signaling 3 (SOCS3). Int J Tryptophan Res (2010) 3:91-7. doi:10.4137/IJTR.S3971
22. Albini E, Rosini V, Gargaro M, Mondanelli G, Belladonna ML, Pallotta MT, et al. Distinct roles of immunoreceptor tyrosine-based motifs in immunosuppressive indoleamine 2,3-dioxygenase 1. J Cell Mol Med (2017) 21:165-76. doi:10.1111/jcmm.12954
23. Orabona C, Pallotta M, Grohmann U. Different partners, opposite outcomes: a new perspective of the immunobiology of indoleamine 2,3-dioxygenase. Mol Med (2012) 18:834-42. doi:10.2119/molmed.2012.00029
24. Mondanelli G, Bianchi R, Pallotta MT, Orabona C, Albini E, Iacono A, et al. A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells. Immunity (2017) 46:233-44. doi:10.1016/j.immuni.2017.01.005
25. Bessede A, Gargaro M, Pallotta MT, Matino D, Brunacci C, Bicciato S, et al. Aryl hydrocarbon receptor control of a disease tolerance defense pathway. Nature (2015) 511:184-90. doi:10.1038/nature13323.Aryl
26. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol (2013) 34:137-43. doi:10.1016/j.it.2012.10.001
27. Schmidt SV, Schultze JL. New insights into IDO biology in bacterial and viral infections. Front Immunol (2014) 5:384. doi:10.3389/fimmu.2014.00384
28. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science (1998) 281:1191-3. doi:10.1126/science.281.5380.1191
29. Heng B, Lim CK, Lovejoy DB, Bessede A, Gluch L, Guillemin GJ. Understanding the role of the kynurenine pathway in human breast cancer immunobiology. Oncotarget (2016) 7:6506-20. doi:10.18632/oncotarget.6467
30. Zaher SS, Germain C, Fu H, Larkin DFP, George AJT. 3-hydroxykynurenine suppresses CD4+ T-cell proliferation, induces T-regulatory-cell development, and prolongs corneal allograft survival. Invest Ophthalmol Vis Sci (2011) 52:2640-8. doi:10.1167/iovs.10-5793
31. Prodinger J, Loacker LJ, Schmidt RLJ, Ratzinger F, Greiner G, Witzeneder N, et al. The tryptophan metabolite picolinic acid suppresses proliferation and metabolic activity of CD4+ T cells and inhibits c-Myc activation. J Leukoc Biol (2016) 99:583-94. doi:10.1189/jlb.3A0315-135R
32. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol (2002) 3:1097-101. doi:10.1038/ni846
33. Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev (2008) 222:206-21. doi:10.1111/j.1600-065X.2008.00610.x
34. Löb S, Königsrainer A, Zieker D, Brücher BLDM, Rammensee HG, Opelz G, et al. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother (2009) 58:153-7. doi:10.1007/s00262-008-0513-6
35. Godin-Ethier J, HanafiL-A, Piccirillo CA, Lapointe R. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res (2011) 17:6985-91. doi:10.1158/1078-0432.CCR-11-1331
36. Qin Y, Ekmekcioglu S, Forget M-A, Szekvolgyi L, Hwu P, Grimm EA, et al. Cervical cancer neoantigen landscape and immune activity is associated with human papillomavirus master regulators. Front Immunol (2017) 8:689. doi:10.3389/fimmu.2017.00689
37. Foy JP, Bertolus C, Michallet MC, Deneuve S, Incitti R, Bendriss-Vermare N, et al. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade. Ann Oncol (2017) 28:1934-41. doi:10.1093/annonc/mdx210
38. Rovira Gonzalez YI, Lynch PJ, Thompson EE, Stultz BG, Hursh DA. In vitro cytokine licensing induces persistent permissive chromatin at the Indoleamine 2,3-dioxygenase promoter. Cytotherapy (2016) 18:1114-28. doi:10.1016/j.jcyt.2016.05.017
39. Carbotti G, Barisione G, Airoldi I, Mezzanzanica D, Bagnoli M, Ferrero S, et al. IL-27 induces the expression of IDO and PD-L1 in human cancer cells. Oncotarget (2015) 6:43267-80. doi:10.18632/oncotarget.6530
40. Belladonna ML, Orabona C, Grohmann U, Puccetti P. TGF-ß and kynurenines as the key to infectious tolerance. Trends Mol Med (2009) 15:41-9. doi:10.1016/j.molmed.2008.11.006
41. Yanagawa Y, Iwabuchi K, Onoé K. Co-operative action of interleukin-10 and interferon-γ to regulate dendritic cell functions. Immunology (2009) 127:345-53. doi:10.1111/j.1365-2567.2008.02986.x
42. Novitskiy SV, Ryzhov S, Zaynagetdinov R, Goldstein AE, Huang Y, Tikhomirov OY, et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood (2008) 112:1822-31. doi:10.1182/blood-2008-02-136325
43. Hennequart M, Pilotte L, Cane S, Hoffmann D, Stroobant V, De Plaen E, et al. Constitutive IDO1 expression in human tumors is driven by cyclooxygenase-2 and mediates intrinsic immune resistance. Cancer Immunol Res (2017) 5:695-709. doi:10.1158/2326-6066.CIR-16-0400
44. Pietra G, Vitale M, Moretta L, Mingari MC. How melanoma cells inactivate NK cells. Oncoimmunology (2012) 1:974-5. doi:10.4161/onci.20405
45. Wang D, Saga Y, Mizukami H, Sato N, Nonaka H, Fujiwara H, et al. Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy. Int J Oncol (2012) 40:929-34. doi:10.3892/ijo.2011.1295
46. Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol (2002) 168:3771-6. doi:10.4049/jimmunol.168.8.3771
47. Li Q, Harden JL, Anderson CD, Egilmez NK. Tolerogenic phenotype of IFN-γ-induced IDO+ dendritic cells is maintained via an autocrine IDO-kynurenine/AhR-IDO loop. J Immunol (2016) 197:962-70. doi:10.4049/jimmunol.1502615
48. Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, et al. Tumor-expressed IDO recruits and activates MDSCs in a treg-dependent manner. Cell Rep (2015) 13:412-24. doi:10.1016/j.celrep.2015.08.077
49. Powell JJD, Pollizzi KNK, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annu Rev immunol (2012) 30:39-68. doi:10.1146/annurev-immunol-020711-075024.Regulation
50. Kim R, Emi M, Tanabe K. Cancer immunoediting: from immune surveillance to immune escape. Immunology (2007) 121:1-17. doi:10.1111/j.1365-2567.2007.02587.x
51. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol (2004) 22:329-60. doi:10.1146/annurev.immunol.22.012703.104803
52. Shou D, Liang W, Song Z, Yin J, Sun Q, Gong W. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies. Oncotarget (2016) 7:64505-11. doi:10.18632/oncotarget.11352
53. Zhao Q, Kuang D-M, Wu Y, Xiao X, Li X-F, Li T-J, et al. Activated CD69+ T cells foster immune privilege by regulating IDO expression in tumor-associated macrophages. J Immunol (2012) 188:1117-24. doi:10.4049/jimmunol.1100164
54. Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res (2005) 11:6030-9. doi:10.1158/1078-0432.CCR-04-2671
55. Hascitha J, Priya R, Jayavelu S, Dhandapani H, Selvaluxmy G, Sunder Singh S, et al. Analysis of kynurenine/tryptophan ratio and expression of IDO1 and 2 mRNA in tumour tissue of cervical cancer patients. Clin Biochem (2016) 49:919-24. doi:10.1016/j.clinbiochem.2016.04.008
56. Zhai L, Ladomersky E, Lauing KL, Wu M, Genet M, Gritsina G, et al. Infiltrating T cells increase IDO1 expression in glioblastoma and contribute to decreased patient survival. Clin Cancer Res (2017) 23:6650-60. doi:10.1158/1078-0432.CCR-17-0120
57. Xin Y, Cai H. Improved radiosynthesis and biological evaluations of L- and D-1-[18F]fluoroethyl-tryptophan for PET imaging of IDO-mediated kynurenine pathway of tryptophan metabolism. Mol Imaging Biol (2017) 19:589-98. doi:10.1007/s11307-016-1024-z
58. Henrottin J, Lemaire C, Egrise D, Zervosen A, van Den Eynde B, Plenevaux A, et al. Fully automated radiosynthesis of N1-[18F]fluoroethyl-tryptophan and study of its biological activity as a new potential substrate for indoleamine 2,3-dioxygenase PET imaging. Nucl Med Biol (2016) 43:379-89. doi:10.1016/j.nucmedbio.2016.03.001
59. Munn DH, Mellor AL. IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol (2016) 37:193-207. doi:10.1016/j.it.2016.01.002
60. Routy JP, Routy B, Graziani GM, Mehraj V. The kynurenine pathway is a double-edged sword in immune-privileged sites and in cancer: implications for immunotherapy. Int J Tryptophan Res (2016) 9:67-77. doi:10.4137/IJTR.S38355
61. Kozlowska A, Mackiewicz J, Mackiewicz A. Therapeutic gene modified cell based cancer vaccines. Gene (2013) 525:200-7. doi:10.1016/j.gene.2013.03.056
62. Brochez L, Chevolet I, Kruse V. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. Eur J Cancer (2017) 76:167-82. doi:10.1016/j.ejca.2017.01.011
63. Vacchelli E, Aranda F, Eggermont A, Sautès-Fridman C, Tartour E, Kennedy EP, et al. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology (2014) 3:e957994. doi:10.4161/21624011.2014.957994
64. Liu Y, Liang X, Yin X, Lv J, Tang K, Ma J, et al. Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells. Nat Commun (2017) 8:15207. doi:10.1038/ncomms15207
65. Garg AD, Vandenberk L, Van Woensel M, Belmans J, Schaaf M, Boon L, et al. Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma. Oncoimmunology (2017) 6:e1295903. doi:10.1080/2162402X.2017.1295903
66. Blache CA, Manuel ER, Kaltcheva TI, Wong AN, Ellenhorn JDI, Blazar BR, et al. Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth. Cancer Res (2012) 72:6447-56. doi:10.1158/0008-5472.CAN-12-0193
67. Manuel ER, Diamond DJ. A road less traveled paved by IDO silencing: harnessing the antitumor activity of neutrophils. Oncoimmunology (2013) 2:e23322. doi:10.4161/onci.23322